Bayer banks €3bn in Apollo contraceptives division deal
Bayer has sold a stake in its newly established contraceptives offshoot to global asset management firm Apollo for €3bn ($3.4bn)…
10 Jul 2026
Chinese biotech MindRank secures $52m to advance AI-designed oral GLP-1RA
MindRank has raised $52m to advance its pipeline of candidates discovered and designed by artificial intelligence (AI), including a lead glucagon-like peptide-1 receptor agonist (GLP-1RA) currently in a Phase III…
10 Jul 2026
Ipsen set to rival Botox after duo of Phase III migraine wins
Ipsen Pharmaceuticals’ Dysport (abobotulinumtoxinA), a Botox (onabotulinumtoxinA) competitor, could be on track for a label expansion after the drug posted a double Phase III win in two migraine indications. Within…
10 Jul 2026
Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS). Under the deal, Teva will hold…
10 Jul 2026
Apertura and NIH institutes to test gene therapy for NPC1
Apertura has entered a cooperative research and development agreement (CRADA) with various NIH institutes for a gene therapy to treat Niemann-Pick Disease Type C1 (NPC1). The company signed the agreement…
09 Jul 2026
Moderna secures up to 24 million RSV vaccine dose contract with Europe
Moderna has agreed a contract with the European Commission (EC) that will see tens of millions of respiratory syncytial virus (RSV) vaccine doses accessible to member countries in time for…
09 Jul 2026
Sino and AstraZeneca sign licence agreement for TQC3721
AstraZeneca and Sino Biopharmaceutical's subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have signed an exclusive licence agreement for TQC3721. AstraZeneca will obtain a licence to develop, manufacture and commercialise the…